Spectrum extends tender offer for shares of Allos Therapeutics

Tuesday, July 10, 2012 11:31 AM

Spectrum Pharmaceuticals, a biotech with a primary focus in oncology and hematology, has extended the offer period for its tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics, a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, for $1.82 per share in cash.

The offer, which was previously scheduled to expire at 5 p.m. ET, on July 9, 2012, has been extended until 5 p.m. ET on July 23, 2012, unless extended for an additional period. All terms and conditions of the tender offer shall remain unchanged during the extended period.

As of 5 p.m. ET on July 6, 2012, a total of approximately 63,574,257 shares of Allos common stock, representing approximately 59.4% of the outstanding shares of Allos common stock, were validly tendered and not withdrawn.

On June 21, 2012, Spectrum was informed by Allos that the European Commission had adopted the recommendation against the approval of Folotyn and there was no longer any possibility that such milestones would be achieved. Accordingly, no value should be ascribed to the Contingent Value Right and the price for each share of common stock of Allos will be $1.82 per share in cash, without interest and less any applicable withholding taxes. The extension was made in order for Spectrum and Allos to continue cooperating with the Federal Trade Commission (FTC) in relation to a Request for Additional Information and Documentary Material that each party received on May 9, 2012, from the FTC.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 22

Roche/Genentech plans pilot trial to measure patientpreference for participating at home v. at study site

Bipartisan 21st Century Cures initiative prepares to draft legislation to accelerate biomedical R&D, lower cost

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs